Global Exenatide Market
Global Exenatide Market

Exenatide Comprehensive Study by Type (Extended-release injectable suspension, Fast release injectable suspension), Application (Hospital, Drug store) Players and Region - Global Market Outlook to 2026

Exenatide Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 201 Pages 181 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Exenatide Market Overview:
Exenatide is a drug used to treat diabetes mellitus type 2 and is marketed under the brand names Byetta and Bydureon, among others. It is used in conjunction with a healthy diet, regular exercise, and possibly other anti-diabetic medications. After metformin and sulfonylureas, it is a treatment alternative. It's offered as a subcutaneous injection one hour before the first and last meals of the day.

Growth Drivers
  • Used for Increasing Insulin Release from the Pancreas and Decreases Excessive Glucagon Release
  • Increasing Diabetes Prevalence

Market Trends
  • Rising Research and Development Activities

Roadblocks
  • Side Effects of Exenatide Such as Acid or Sour Stomach, Diarrhea, Heartburn, Indigestion, Nausea, and Vomiting

Opportunities
  • Growing Health Awareness among Consumers
  • Surging Demand from Developing Countries

Challenges
  • Straight Government Regulation


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Novo Nordisk (Denmark), Sanofi (France), Eli Lilly (United States), AstraZeneca (United Kingdom), Teva Pharmaceutical Industries (Israel), Bachem AG ( Switzerland) and Ranbaxy Laboratories Limited (India). Analyst at AMA Research see Global Players to retain maximum share of Global Exenatide market by 2026.

In March 2011, Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

What Can be Explored with the Exenatide Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Exenatide Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Exenatide
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Exenatide market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Exenatide market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Exenatide, Suppliers and Distributors of Exenatide, Venture Capitalists and Private Equity Firms and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Extended-release injectable suspension
  • Fast release injectable suspension
By Application
  • Hospital
  • Drug store
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Used for Increasing Insulin Release from the Pancreas and Decreases Excessive Glucagon Release
      • 3.2.2. Increasing Diabetes Prevalence
    • 3.3. Market Challenges
      • 3.3.1. Straight Government Regulation
    • 3.4. Market Trends
      • 3.4.1. Rising Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Exenatide, by Type, Application and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Exenatide (Value)
      • 5.2.1. Global Exenatide by: Type (Value)
        • 5.2.1.1. Extended-release injectable suspension
        • 5.2.1.2. Fast release injectable suspension
      • 5.2.2. Global Exenatide by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Drug store
      • 5.2.3. Global Exenatide Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Exenatide (Price)
      • 5.3.1. Global Exenatide by: Type (Price)
  • 6. Exenatide: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novo Nordisk (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bachem AG ( Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ranbaxy Laboratories Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Exenatide Sale, by Type, Application and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Exenatide (Value)
      • 7.2.1. Global Exenatide by: Type (Value)
        • 7.2.1.1. Extended-release injectable suspension
        • 7.2.1.2. Fast release injectable suspension
      • 7.2.2. Global Exenatide by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Drug store
      • 7.2.3. Global Exenatide Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Exenatide (Price)
      • 7.3.1. Global Exenatide by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Exenatide: by Type(USD Million)
  • Table 2. Exenatide Extended-release injectable suspension , by Region USD Million (2015-2020)
  • Table 3. Exenatide Fast release injectable suspension , by Region USD Million (2015-2020)
  • Table 4. Exenatide: by Application(USD Million)
  • Table 5. Exenatide Hospital , by Region USD Million (2015-2020)
  • Table 6. Exenatide Drug store , by Region USD Million (2015-2020)
  • Table 7. South America Exenatide, by Country USD Million (2015-2020)
  • Table 8. South America Exenatide, by Type USD Million (2015-2020)
  • Table 9. South America Exenatide, by Application USD Million (2015-2020)
  • Table 10. Brazil Exenatide, by Type USD Million (2015-2020)
  • Table 11. Brazil Exenatide, by Application USD Million (2015-2020)
  • Table 12. Argentina Exenatide, by Type USD Million (2015-2020)
  • Table 13. Argentina Exenatide, by Application USD Million (2015-2020)
  • Table 14. Rest of South America Exenatide, by Type USD Million (2015-2020)
  • Table 15. Rest of South America Exenatide, by Application USD Million (2015-2020)
  • Table 16. Asia Pacific Exenatide, by Country USD Million (2015-2020)
  • Table 17. Asia Pacific Exenatide, by Type USD Million (2015-2020)
  • Table 18. Asia Pacific Exenatide, by Application USD Million (2015-2020)
  • Table 19. China Exenatide, by Type USD Million (2015-2020)
  • Table 20. China Exenatide, by Application USD Million (2015-2020)
  • Table 21. Japan Exenatide, by Type USD Million (2015-2020)
  • Table 22. Japan Exenatide, by Application USD Million (2015-2020)
  • Table 23. India Exenatide, by Type USD Million (2015-2020)
  • Table 24. India Exenatide, by Application USD Million (2015-2020)
  • Table 25. South Korea Exenatide, by Type USD Million (2015-2020)
  • Table 26. South Korea Exenatide, by Application USD Million (2015-2020)
  • Table 27. Taiwan Exenatide, by Type USD Million (2015-2020)
  • Table 28. Taiwan Exenatide, by Application USD Million (2015-2020)
  • Table 29. Australia Exenatide, by Type USD Million (2015-2020)
  • Table 30. Australia Exenatide, by Application USD Million (2015-2020)
  • Table 31. Rest of Asia-Pacific Exenatide, by Type USD Million (2015-2020)
  • Table 32. Rest of Asia-Pacific Exenatide, by Application USD Million (2015-2020)
  • Table 33. Europe Exenatide, by Country USD Million (2015-2020)
  • Table 34. Europe Exenatide, by Type USD Million (2015-2020)
  • Table 35. Europe Exenatide, by Application USD Million (2015-2020)
  • Table 36. Germany Exenatide, by Type USD Million (2015-2020)
  • Table 37. Germany Exenatide, by Application USD Million (2015-2020)
  • Table 38. France Exenatide, by Type USD Million (2015-2020)
  • Table 39. France Exenatide, by Application USD Million (2015-2020)
  • Table 40. Italy Exenatide, by Type USD Million (2015-2020)
  • Table 41. Italy Exenatide, by Application USD Million (2015-2020)
  • Table 42. United Kingdom Exenatide, by Type USD Million (2015-2020)
  • Table 43. United Kingdom Exenatide, by Application USD Million (2015-2020)
  • Table 44. Netherlands Exenatide, by Type USD Million (2015-2020)
  • Table 45. Netherlands Exenatide, by Application USD Million (2015-2020)
  • Table 46. Rest of Europe Exenatide, by Type USD Million (2015-2020)
  • Table 47. Rest of Europe Exenatide, by Application USD Million (2015-2020)
  • Table 48. MEA Exenatide, by Country USD Million (2015-2020)
  • Table 49. MEA Exenatide, by Type USD Million (2015-2020)
  • Table 50. MEA Exenatide, by Application USD Million (2015-2020)
  • Table 51. Middle East Exenatide, by Type USD Million (2015-2020)
  • Table 52. Middle East Exenatide, by Application USD Million (2015-2020)
  • Table 53. Africa Exenatide, by Type USD Million (2015-2020)
  • Table 54. Africa Exenatide, by Application USD Million (2015-2020)
  • Table 55. North America Exenatide, by Country USD Million (2015-2020)
  • Table 56. North America Exenatide, by Type USD Million (2015-2020)
  • Table 57. North America Exenatide, by Application USD Million (2015-2020)
  • Table 58. United States Exenatide, by Type USD Million (2015-2020)
  • Table 59. United States Exenatide, by Application USD Million (2015-2020)
  • Table 60. Canada Exenatide, by Type USD Million (2015-2020)
  • Table 61. Canada Exenatide, by Application USD Million (2015-2020)
  • Table 62. Mexico Exenatide, by Type USD Million (2015-2020)
  • Table 63. Mexico Exenatide, by Application USD Million (2015-2020)
  • Table 64. Exenatide: by Type(USD/Units)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Exenatide: by Type(USD Million)
  • Table 73. Exenatide Extended-release injectable suspension , by Region USD Million (2021-2026)
  • Table 74. Exenatide Fast release injectable suspension , by Region USD Million (2021-2026)
  • Table 75. Exenatide: by Application(USD Million)
  • Table 76. Exenatide Hospital , by Region USD Million (2021-2026)
  • Table 77. Exenatide Drug store , by Region USD Million (2021-2026)
  • Table 78. South America Exenatide, by Country USD Million (2021-2026)
  • Table 79. South America Exenatide, by Type USD Million (2021-2026)
  • Table 80. South America Exenatide, by Application USD Million (2021-2026)
  • Table 81. Brazil Exenatide, by Type USD Million (2021-2026)
  • Table 82. Brazil Exenatide, by Application USD Million (2021-2026)
  • Table 83. Argentina Exenatide, by Type USD Million (2021-2026)
  • Table 84. Argentina Exenatide, by Application USD Million (2021-2026)
  • Table 85. Rest of South America Exenatide, by Type USD Million (2021-2026)
  • Table 86. Rest of South America Exenatide, by Application USD Million (2021-2026)
  • Table 87. Asia Pacific Exenatide, by Country USD Million (2021-2026)
  • Table 88. Asia Pacific Exenatide, by Type USD Million (2021-2026)
  • Table 89. Asia Pacific Exenatide, by Application USD Million (2021-2026)
  • Table 90. China Exenatide, by Type USD Million (2021-2026)
  • Table 91. China Exenatide, by Application USD Million (2021-2026)
  • Table 92. Japan Exenatide, by Type USD Million (2021-2026)
  • Table 93. Japan Exenatide, by Application USD Million (2021-2026)
  • Table 94. India Exenatide, by Type USD Million (2021-2026)
  • Table 95. India Exenatide, by Application USD Million (2021-2026)
  • Table 96. South Korea Exenatide, by Type USD Million (2021-2026)
  • Table 97. South Korea Exenatide, by Application USD Million (2021-2026)
  • Table 98. Taiwan Exenatide, by Type USD Million (2021-2026)
  • Table 99. Taiwan Exenatide, by Application USD Million (2021-2026)
  • Table 100. Australia Exenatide, by Type USD Million (2021-2026)
  • Table 101. Australia Exenatide, by Application USD Million (2021-2026)
  • Table 102. Rest of Asia-Pacific Exenatide, by Type USD Million (2021-2026)
  • Table 103. Rest of Asia-Pacific Exenatide, by Application USD Million (2021-2026)
  • Table 104. Europe Exenatide, by Country USD Million (2021-2026)
  • Table 105. Europe Exenatide, by Type USD Million (2021-2026)
  • Table 106. Europe Exenatide, by Application USD Million (2021-2026)
  • Table 107. Germany Exenatide, by Type USD Million (2021-2026)
  • Table 108. Germany Exenatide, by Application USD Million (2021-2026)
  • Table 109. France Exenatide, by Type USD Million (2021-2026)
  • Table 110. France Exenatide, by Application USD Million (2021-2026)
  • Table 111. Italy Exenatide, by Type USD Million (2021-2026)
  • Table 112. Italy Exenatide, by Application USD Million (2021-2026)
  • Table 113. United Kingdom Exenatide, by Type USD Million (2021-2026)
  • Table 114. United Kingdom Exenatide, by Application USD Million (2021-2026)
  • Table 115. Netherlands Exenatide, by Type USD Million (2021-2026)
  • Table 116. Netherlands Exenatide, by Application USD Million (2021-2026)
  • Table 117. Rest of Europe Exenatide, by Type USD Million (2021-2026)
  • Table 118. Rest of Europe Exenatide, by Application USD Million (2021-2026)
  • Table 119. MEA Exenatide, by Country USD Million (2021-2026)
  • Table 120. MEA Exenatide, by Type USD Million (2021-2026)
  • Table 121. MEA Exenatide, by Application USD Million (2021-2026)
  • Table 122. Middle East Exenatide, by Type USD Million (2021-2026)
  • Table 123. Middle East Exenatide, by Application USD Million (2021-2026)
  • Table 124. Africa Exenatide, by Type USD Million (2021-2026)
  • Table 125. Africa Exenatide, by Application USD Million (2021-2026)
  • Table 126. North America Exenatide, by Country USD Million (2021-2026)
  • Table 127. North America Exenatide, by Type USD Million (2021-2026)
  • Table 128. North America Exenatide, by Application USD Million (2021-2026)
  • Table 129. United States Exenatide, by Type USD Million (2021-2026)
  • Table 130. United States Exenatide, by Application USD Million (2021-2026)
  • Table 131. Canada Exenatide, by Type USD Million (2021-2026)
  • Table 132. Canada Exenatide, by Application USD Million (2021-2026)
  • Table 133. Mexico Exenatide, by Type USD Million (2021-2026)
  • Table 134. Mexico Exenatide, by Application USD Million (2021-2026)
  • Table 135. Exenatide: by Type(USD/Units)
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Exenatide: by Type USD Million (2015-2020)
  • Figure 5. Global Exenatide: by Application USD Million (2015-2020)
  • Figure 6. South America Exenatide Share (%), by Country
  • Figure 7. Asia Pacific Exenatide Share (%), by Country
  • Figure 8. Europe Exenatide Share (%), by Country
  • Figure 9. MEA Exenatide Share (%), by Country
  • Figure 10. North America Exenatide Share (%), by Country
  • Figure 11. Global Exenatide: by Type USD/Units (2015-2020)
  • Figure 12. Global Exenatide share by Players 2020 (%)
  • Figure 13. Global Exenatide share by Players (Top 3) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 16. Novo Nordisk (Denmark) Revenue: by Geography 2020
  • Figure 17. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi (France) Revenue: by Geography 2020
  • Figure 19. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 21. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2020
  • Figure 25. Bachem AG ( Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Bachem AG ( Switzerland) Revenue: by Geography 2020
  • Figure 27. Ranbaxy Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 28. Ranbaxy Laboratories Limited (India) Revenue: by Geography 2020
  • Figure 29. Global Exenatide: by Type USD Million (2021-2026)
  • Figure 30. Global Exenatide: by Application USD Million (2021-2026)
  • Figure 31. South America Exenatide Share (%), by Country
  • Figure 32. Asia Pacific Exenatide Share (%), by Country
  • Figure 33. Europe Exenatide Share (%), by Country
  • Figure 34. MEA Exenatide Share (%), by Country
  • Figure 35. North America Exenatide Share (%), by Country
  • Figure 36. Global Exenatide: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Novo Nordisk (Denmark)
  • Sanofi (France)
  • Eli Lilly (United States)
  • AstraZeneca (United Kingdom)
  • Teva Pharmaceutical Industries (Israel)
  • Bachem AG ( Switzerland)
  • Ranbaxy Laboratories Limited (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation